Psychemedics Corp. (PMD)
US Market

Psychemedics (PMD) Income Statement


Psychemedics Income Statement

Last quarter (Q4 2023), Psychemedics's total revenue was $5.00M, a decrease of -12.36% from the same quarter last year. In Q4, Psychemedics's net income was $-945.00K. See Psychemedics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 22.10M$ 22.10M$ 25.24M$ 24.91M$ 21.36M$ 37.68M
Cost of Revenue
$ 6.38M$ 13.69M$ 15.95M$ -14.64M$ 16.47M$ 21.23M
Gross Profit
$ 8.41M$ 8.41M$ 9.29M$ 10.26M$ 4.89M$ 16.44M
Operating Expense
$ 5.87M$ 11.33M$ 10.37M$ -10.05M$ 10.95M$ 13.45M
Operating Income
$ 3.99M$ -2.92M$ -1.08M$ -24.70M$ -6.07M$ 3.00M
Net Non Operating Interest Income Expense
$ -17.00K$ -17.00K$ -32.00K$ -3.15M--
Other Income Expense
$ -6.36M$ -497.00K$ -43.00K$ -27.15M$ -140.00K$ 58.00K
Pretax Income
$ -3.44M$ -3.44M$ -1.04M$ -821.00K$ -6.21M$ 3.06M
Tax Provision
$ 1.01M$ 716.00K$ 44.00K$ -156.00K$ -2.35M$ 1.51M
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ 8.32M$ -4.15M$ -1.08M$ -543.00K$ -3.86M$ 1.54M
Basic EPS
$ -0.72$ -0.72$ -0.19$ -0.12$ -0.70$ 0.28
Diluted EPS
$ -0.72$ -0.72$ -0.19$ -0.12$ -0.70$ 0.28
Basic Average Shares
$ 22.96M$ 5.74M$ 5.63M$ 5.55M$ 5.52M$ 5.51M
Diluted Average Shares
$ 22.96M$ 5.74M$ 5.63M$ 5.55M$ 5.52M$ 5.53M
Dividend Per Share
$ 0.14-$ 0.21-$ 0.18$ 0.72
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
-----$ 0.44
Rent Expense Supplemental
Total Expenses
$ 12.24M$ 25.02M$ 26.32M$ -24.70M$ 27.43M$ 34.68M
Net Income From Continuing And Discontinued Operation
$ -4.15M$ -4.15M$ -1.08M$ -543.00K$ -3.86M$ 1.54M
Normalized Income
$ -2.68M$ -2.71M$ -810.60K-$ -3.86M$ 1.54M
Interest Expense
$ -2.41M$ -2.41M$ -1.01M$ -870.00K$ -6.07M$ 3.00M
$ 263.00K$ 263.00K$ 2.31M$ 2.82M$ -2.44M$ 5.91M
Currency in USD

Psychemedics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis